This article shall describe the role of (18)F-Sodium Fluoride ((18)F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. (18)F-NaF PET was initially utilised as a bone scanning agent in the 1960s and early 1970s, however its usage was restricted by the then available gamma cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its usage and role. After a brief introduction, this paper will describe the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of (18)F-NaF. The performance of (18)F-NaF PET/CT is then compared with conventional bone scintigraphy utilizing current evidence from the literature. Strengths and weaknesses of (18)F-NaF PET/CT imaging shall be highlighted. Clinical examples of improved accuracy of diagnosis and impact on patient management shall be illustrated. Limitations of (18)F-NaF PET/CT imaging will be outlined.
Journal of nuclear medicine technology. 2016 Sep 15 [Epub ahead of print]
Randeep Kulshrestha, Sobhan Vinjamuri, Andrew England, Julie Nightingale, Peter Hogg
Queensland X-ray, Australia;, Royal Liverpool Hospital, United Kingdom;, University of Salford, United Kingdom.